Business Wire

EcoOnline Celebrates Longstanding Partnership with Menzies Aviation, Driving Safety Culture Across the Globe

16.1.2025 09:00:00 CET | Business Wire | Press release

Share

EcoOnline is proud to celebrate the continued success of its partnership with Menzies Aviation, the leading service partner to the world’s airports and airlines. Since 2019, EcoOnline has played a key role in enhancing the company’s MORSE (Menzies Operating Responsibly, Safely and Efficiently) system, driving safety culture and compliance across the company’s global network.

With a presence at more than 295 airports in over 65 countries, Menzies Aviation operates in high-risk environments, where safety is embedded in its DNA. As Malcolm Rae, Head of Risk Systems & Data at Menzies, reflects, “We influence safety from the moment passengers walk into an airport to when they leave. We live and breathe it day in, day out—not just in the risk and safety team, but every employee takes it extremely seriously.”

Technology That Drives Safety at Every Level

The longstanding collaboration with EcoOnline has enabled Menzies Aviation to implement a more efficient, data-driven approach to incident reporting, risk management and compliance tracking. Using EcoOnline’s advanced EHS (environment, health, and safety) solution—the technology behind Menzies’ MORSE reporting system—employees are empowered to quickly identify risks, make informed decisions, and proactively address safety risks in real time.

Since adopting EcoOnline’s platform in 2019, Menzies has seen remarkable improvements:

  • 128% increase in employee hazard reporting.
  • Serious personal injury reduced from 1.8 per 1,000 full-time employees in 2019 to 0.94 in 2022 and 0.7 in 2023.

"If you want to be an industry leader, you've got to know where your risks are, and that starts with empowering every employee to act. EcoOnline’s EHS platform equips everyone with the tools to report hazards and ensure our people go home safely," said Graham Cowing, Vice President of Safety Standards, Menzies Aviation.

Board Commitment to Safety

Safety at Menzies is championed at every level, from frontline workers to the boardroom. Graham commented:"Safety is a core value that starts with leadership. Every executive member is committed to getting involved, and initiatives like ‘Take 10 for Safety,’ where every board meeting begins with a safety-focused discussion, are supported by real-time dashboards from EcoOnline. These insights keep safety central to decision-making and drive accountability across the organisation."

MORSE: A system, culture and celebration

Menzies’ approach to safety is defined by its MORSE cultural mindset, MORSE safety systems, and immersive bi-annual MORSE Week events. Its most recent MORSE Week, which took place from 28 October – 1 November 2024 focused on emergency response planning, offering tools, support, and guidance to help its global teams reaffirm their commitment to safety through learning and team-building opportunities.

Tom Goodmanson, CEO of EcoOnline, commented, "By prioritising safety and collaboration, Menzies Aviation—together with EcoOnline—is setting new benchmarks for industry standards, ensuring a safer, more secure environment for employees and customers. It’s impressive that Graham still says, ‘more work is to be done,’ as it reflects Menzies’ commitment to continuous improvement."

Learn from Menzies’ safety success—explore the full case study here.

Visit ecoonline.com to immediately and positively impact your workplace safety and sustainability.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250116891021/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye